logo
Share SHARE
FONT-SIZE Plus   Neg

Aeterna Zentaris' Phase3 Perifosine Trial Fails To Meet Primary Endpoint

Late-stage oncology drug development company Aeterna Zentaris Inc. (AEZS: Quote, AEZ.TO) said its Phase 3 trial evaluating perifosine in refractory advanced colorectal cancer patients failed to meet primary endpoint. Trading for Aeterna halted in early morning hours and shares are currently down more than 55 percent on the Nasdaq.

The focus of the X-PECT study was improvement of overall survival with perifosine in comparison with capecitabine + placebo. The trial involved 468 patients in 65 sites in the U.S and the study was conducted by the Company's North American licensee partner, Keryx Biopharmaceuticals, Inc. (KERX: Quote).

Aeterna Zentaris said it is very disappointed that the trial result. The company will continue further data analyses in collaboration with our licensee partners, in order to determine the future development strategy for perifosine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Online retail giant Amazon.com Inc. (AMZN) is reportedly in talks to buy luxury online fashion retailer Net-a-Porter. The news of acquisition was first reported by Women's Wear Daily, which said the deal would be completed for about 2 billion euros, indicating the biggest acquisition yet by Amazon.... Tim Cook, the CEO of tech giant Apple Inc., in an interview said he intends to give away all his wealth to charity. Cook, in an interview to Fortune, said he plans to donate all his wealth to philanthropic projects after paying for his 10-year old nephew's college education. According to Fortune,... Is it a 'personal life crisis' that led the Germanwings' co-pilot Andreas Lubitz to deliberately lowering the plane carrying 149 people to French Alps mountain? Police is investigating to find evidences to prove this suggestion.
comments powered by Disqus
Follow RTT